Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

BACKGROUND & AIMS Liver biopsy is required to diagnose nonalcoholic steatohepatitis (NASH) in patients with suspected non-alcoholic fatty liver disease (NAFLD); recent studies suggested significant sampling variability. Using percutaneous liver biopsy samples from patients with suspected NAFLD, we examined the relationship between histological yield and length of biopsies, number of cores and number of independent readings. METHODS Three cores of liver tissue were collected, by percutaneous liver biopsy, from each of 50 patients suspected to have NAFLD. The diagnostic yield (percent with definite NASH) and other histological findings from 2 independent, blinded examinations of 2 cores and from all 3 cores combined were assessed. RESULTS Steatosis, lobular inflammation and fibrosis scores were significantly higher when 3 samples were analyzed, compared with 2. However, between groups, there were no significant differences in hepatocyte ballooning, proportion with an NAFLD activity score > or =4 or proportion with definite NASH (57% vs 61%, P = .3). The length of the biopsy sample correlated with percentage of patients found to have definite NASH (29%, 46%, 56%, and 65% in biopsies measuring <10 mm, 10-14 mm, 15-24 mm, and > or =25 mm, respectively; P < .0001). When biopsy specimens were read twice by the same pathologist, the composite of the 2 independent readings yielded a significantly higher yield for several histological features, compared with the first reading. CONCLUSIONS There is a significant relationship between histological yield and sample length and number of independent readings of liver biopsy samples. More studies are needed to optimize the strategy for liver biopsy, to more effectively assess histology in patients with suspected NAFLD.

[1]  J. Goldblum,et al.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[2]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[3]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[4]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[5]  A. Memon,et al.  Sampling Variability on Percutaneous Liver Biopsy in Patients with Chronic Hepatitis C Virus Infection , 2003, Scandinavian journal of gastroenterology.

[6]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[7]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[8]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[9]  B. Neuschwander‐Tetri,et al.  Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2020, Clinical Gastroenterology and Hepatology.

[10]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[11]  H. Blaszyk,et al.  Histologic Variation of Grade and Stage of Non-alcoholic Fatty Liver Disease in Liver Biopsies , 2005, Obesity surgery.

[12]  L. Ferrell,et al.  Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease , 2006, Hepatology.

[13]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[14]  D. Kleiner,et al.  Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. , 2004, Human pathology.

[15]  Steven P. Larson,et al.  Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  A. McCullough Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. , 2006, The New England journal of medicine.

[17]  Eugene R. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[18]  Z. Goodman,et al.  Liver Biopsy in Cirrhotic Patients , 2007, The American Journal of Gastroenterology.

[19]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[20]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[21]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[22]  N. Chalasani,et al.  Unexplained Elevations in Alanine Aminotransferase in Individuals with the Metabolic Syndrome: Results from the Third National Health and Nutrition Survey (NHANES III) , 2005, The American journal of the medical sciences.

[23]  Laura Marelli,et al.  A systematic review of the quality of liver biopsy specimens. , 2006, American journal of clinical pathology.

[24]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.